Vericel Corp. (VCEL)

[cushsix]

interesting............

Needham & Company analyst Chad Messer reiterated a Buy rating and $12 price target on Vericel Corporation (NASDAQ: VCEL) after Phase IIb ixCELL-DCM data presented today at the American College of Cardiology demonstrated a robust reduction in composite clinical cardiac events for ixmyelocel-T versus placebo. Unfortunately data on the secondary endpoints, including NYHA and 6MWT, were confounding with no meaningful differences between the groups, Messer comments. The lack of difference appears to be driven by a troubling placebo effect.